Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
Tingting ChenTong YuShuping ZhuangYiding GengJunwen XueJiayi WangLiqiang AiBo ChenZhangxiang ZhaoYawei LiJinghao WangHaihai LiangYan XuYunyan GuPublished in: British journal of cancer (2022)
In conclusion, 2-GPS could robustly predict BRCAness OvCa at the individual level and extend the population who may benefit from PARP inhibitors.